Navigation Links
3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology
Date:6/29/2012

MENLO PARK, Calif., June 29, 2012 /PRNewswire/ -- 3-V Biosciences, Inc., announced today the appointment of Douglas Buckley, PhD, as Vice President of Biology.  Dr. Buckley brings more than 25 years of experience in the biopharmaceutical industry, and his discoveries and research leadership have resulted in several marketed products and many more in clinical development.

"With our lead antiviral program entering the clinic in the next year, we are committed to building a strong pipeline.  Doug's extensive experience in target identification and prosecution and his track record of successful early-stage drug development will be instrumental to our continued growth," said George Kemble, PhD, 3-V's Chief Scientific Officer.

"I look forward to building upon the early successes of 3-V and developing the next generation of antiviral compounds with this team," said Dr. Buckley.  "3-V has taken a novel approach to antiviral therapies that are less likely to allow viral resistance to develop.  In addition, this approach opens up the possibility of developing high-value therapeutics in other therapeutic areas, making 3-V a compelling story." 

Dr. Buckley joins 3-V from Exelixis, Inc., where he served most recently as Vice President of Biochemistry.  In that role, he led research and discovery teams responsible for delivering over thirty IND-ready compounds to Exelixis' internal pipeline and to external partnerships.  Also during his tenure at Exelixis, Dr. Buckley contributed to the New Drug Application filing for cabozantinib (XL 184).   Prior to Exelixis, Dr. Buckley was the Department Head of Protein Chemistry and Process Development at Scios, Inc., where he was responsible for process and assay development for two marketed biotherapeutic products (Fiblast® (trafermin) and NATRECOR® (nesiritide)).  Doug received his AB in Chemistry and Economics from Bowdoin College, his PhD in Endocrinology from the Hormone Research Laboratory at the University of California, San Francisco, and his post-doctoral training in the Molecular Biology Department at Massachusetts General Hospital and the Department of Genetics at Harvard Medical School.  Doug serves on the Astia Life Sciences Board as an advisor to women entrepreneurs starting life sciences companies and as a scientific advisor to Woodside Capital Partners.

About 3-V Biosciences

3-V Biosciences, Inc. is a privately held biopharmaceutical company that discovers and develops antiviral therapeutics designed to have broad-spectrum activity, a high barrier to resistance and efficacy against emergent viral strains.  The 3-V team applies an integrated approach with internal expertise in virology, biology, drug discovery and development to drive programs forward.  The company is located in Menlo Park, California.

For additional information on 3-V Biosciences, please visit www.3vbio.com.

Contact information

Stephen R. Brady
Chief Business Officer
650-561-8600


'/>"/>
SOURCE 3-V Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
2. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
3. UCLAs Yi Tang receives Presidential Green Chemistry Challenge Award from EPA
4. President, CEO Leppävuori, VTT: Finland should create a national bioeconomy strategy
5. Oligonucleotide Delivery: Biology, Engineering and Development Conference
6. GW announces creation of Computational Biology Institute to conduct integrated research
7. MARC travel award announced for the 2012 GSA Yeast Genetics and Molecular Biology Meeting
8. Infection biology: The elusive third factor
9. Tips from the Journals of the American Society for Microbiology
10. MARC travel awards announced for the Society for Developmental Biology 71st Annual Meeting
11. The American Society for Microbiology honors Anthony R. Richardson
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2016)... 2016  Extenua Inc., a pioneering developer of ... and access of ubiquitous on-premise and cloud storage, today ... Cyber.  ... C4ISR and Cyber initiatives in support of National ... technology solutions," said Steve Visconti , Extenua ...
(Date:1/13/2016)... , January 13, 2016 ... the addition of the  "India Biometrics ... & Forecast (2015-2020)"  report to ... ) has announced the addition of ... Market - Estimation & Forecast (2015-2020)" ...
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016   ... diagnostic products, today announced the closing of a $9 million ... Proceeds from the financing will be used to accelerate the ... for detecting early-stage pressure ulcers. United ... receiving CE Mark approval. The device,s introduction has been met ...
Breaking Biology News(10 mins):
(Date:2/8/2016)... ... February 08, 2016 , ... Information Management Services ( ... The upgrade represents a completely new technical foundation and is so significant it ... responsive design interface, significantly increased speed for search results, a streamlined layout and a ...
(Date:2/8/2016)... Stockton has an active R&D program for the ... area, the Group has a unique research and development center ... in developing Bio Control products. Stockton ... parameters and regulatory guidelines, and is active in more than ... Stockton,s flagship product Timorex Gold ...
(Date:2/6/2016)... , ... February 06, 2016 , ... ... , The Center for Excellence in Education Sponsors Teacher Training Program , ... February 4, 2016 – The Center for Excellence in Education (CEE) will sponsor ...
(Date:2/5/2016)... 5, 2016 Amarantus BioScience Holdings, ... focused on developing products for Regenerative Medicine, Neurology and ... Disease Designation (RPDD) from the US Food and Drug ... MANF was previously granted orphan drug designation (ODD) by ... Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), ...
Breaking Biology Technology: